Cargando…

Genome‐wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma

In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma (PXA) has been newly defined as a variant of the PXA entity. Furthermore, some anaplastic PXA were reported to have extremely poor prognosis which showed a type of pediatric glioblastoma (GBM) mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Taishi, Fukuoka, Kohei, Nakano, Yoshiko, Yamasaki, Kai, Matsushita, Yuko, Yamashita, Satoshi, Ikeda, Junji, Udaka, Naoko, Tanoshima, Reo, Shiba, Norio, Tateishi, Kensuke, Yamanaka, Shoji, Yamamoto, Tetsuya, Hirato, Junko, Ichimura, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361572/
https://www.ncbi.nlm.nih.gov/pubmed/30609203
http://dx.doi.org/10.1111/cas.13903
Descripción
Sumario:In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma (PXA) has been newly defined as a variant of the PXA entity. Furthermore, some anaplastic PXA were reported to have extremely poor prognosis which showed a type of pediatric glioblastoma (GBM) molecular profile. Recent integrated molecular classification for primary central nervous system tumors proposed some differences between histological and molecular features. Herein, in a genome‐wide molecular analysis, we show an extreme aggressive anaplastic PXA that resulted in a pediatric GBM molecular profile. A full implementation of the molecular approach is the key to predict prognosis and decide the treatment strategy for anaplastic PXA.